In older patients treated with warfarin, the use of cotrimoxazole is associated with a higher risk of upper gastrointestinal tract hemorrhage than other common antibiotics, according to research published in the April 12 issue of the Archives of Internal Medicine, as reported by HealthDay News.
In older patients treated with warfarin, the use of cotrimoxazole is associated with a higher risk of upper gastrointestinal (UGI) tract hemorrhage than other common antibiotics, according to research published in the April 12 issue of the Archives of Internal Medicine, as reported by HealthDay News.
Hadas D. Fischer, MD, of the University of Toronto, Toronto, Ontario, Canada, and colleagues analyzed data from a nested case-control study with 134,637 patients, aged 66 or older, who were treated with warfarin for at least 180 days. Of this group, 2,151 cases were hospitalized for UGI tract hemorrhage, and were matched to controls.
Researchers found that cases hospitalized for UGI tract hemorrhage were substantially more likely than controls to have recently been treated with cotrimoxazole (adjusted OR=3.84; 95% CI, 2.33–2.95).
Treatment with ciprofloxacin also was associated with higher risk (adjusted OR=1.94; 95% CI, 1.28–2.95), but amoxicillin; ampicillin; nitrofurantoin; and norfloxacin were not to a significant degree. Cotrimoxazole prescription was associated with a higher risk compared with amoxicillin or ampicillin (OR=2.80; 95% CI, 1.48–5.32).
“Our observations suggest that clinicians should consider antibiotics other than cotrimoxazole in patients receiving warfarin,” the authors concluded. “If alternatives are inappropriate, close monitoring of anticoagulation control is necessary, and temporary reductions in the dosage of warfarin may be required.”
Two co-authors disclosed past employment relationships with Bayer and Pfizer Global Pharmaceuticals.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More